News Releases
- June 20, 2023Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
- June 8, 2023Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
- May 11, 2023Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
- ,
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - February 2024
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top